Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Ultragenyx Pharmaceutical (0LIF) Share Price & Analysis

0 Followers

0LIF Stock Chart & Stats

$15.89-$1.55(-8.88%)
At close: 4:30 PM GMT
$15$20$25Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$15.88 - $17.41
52-Week Range
$12.87 - $41.50
Previous Close
$17.44
Volume
N/A
Average Volume (3M)
9,532
Market Cap
$1.69B
Enterprise Value
$2.45B
Total Cash (Recent Filing)
$266.00M
Total Debt (Recent Filing)
$1.19B
Price to Earnings (P/E)
―
Beta
0.96
Next Earnings
Feb 18, 2027 (Est.)
EPS Estimate
-0.71
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Gross Margin

Strong revenue expansion combined with high gross margins indicates growing commercial adoption of Ultragenyx’s rare-disease medicines and attractive product economics. If sustained, this profile can support reinvestment, improve operating leverage, and provide a durable foundation for eventual profitability.

Expanded Approved Product Portfolio

Adding two gene therapies broadens the commercial platform and increases the number of products capable of contributing to future growth. The approvals also strengthen Ultragenyx’s position in high-need genetic diseases, while active treatment-center preparation supports eventual market adoption.

Nondilutive Capital And Profitability Plan

The PRV proceeds provide substantial nondilutive funding, while planned R&D reductions and continued product growth offer a defined route toward lower cash consumption. Reaching the 2027 targets would improve financial flexibility and reduce reliance on future equity financing.

Bears Say

Deep Ongoing Losses

Persistent deep losses show that commercial growth has not yet translated into sustainable earnings under the current cost structure. This limits internally generated capital, increases dependence on execution and expense reductions, and leaves profitability sensitive to launch timing and pipeline outcomes.

Significant Cash Burn

Large recurring operating and free-cash-flow outflows indicate that the business is not yet self-funding. Continued burn can constrain investment choices and increase financing sensitivity, particularly if new product launches or cost reductions take longer than management expects to deliver.

Negative Equity And Balance-Sheet Uncertainty

Negative equity reflects accumulated losses that have materially weakened the capital base and reduced financial flexibility. The differing debt figures add uncertainty to the balance-sheet picture, increasing sensitivity to financing conditions until sustained profitability or recapitalization improves resilience.

Ultragenyx Pharmaceutical News

0LIF FAQ

What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest share price was $12.87 and its highest was $41.50 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Ultragenyx Pharmaceutical’s market cap is $1.69B.
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s next earnings report is estimated for Feb 18, 2027 (not yet confirmed), which is in 104 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on Nov 03, 2026. The company reported -$1.16 earnings per share for the quarter, missing the consensus estimate of -$1.1 by -$0.06.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -0.71.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 98,588,875 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$1.16 in its last earnings report, missing expectations of -$1.1. Following the earnings report the stock price went up 4.119%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Hedge funds hold Ultragenyx Pharmaceutical shares: the largest hedge-fund position in Ultragenyx Pharmaceutical is 879,372,568 shares, and hedge funds decreased their holdings by 85.6K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology